Company intelligence / Profile preview

Efranat Ltd.

Ownership: Private
Employees: ~7
Development stage: Other

Overview

Efranat’s lead program EF‑022 demonstrated disease stabilization in approximately 25% of heavily pretreated cancer patients with refractory solid tumors during a Phase I trial. Notably, among those who had progressed after PD‑1 inhibitor therapy, stable disease was observed in about 40%. Compassionate use data for RRP also showed encouraging results. The company aims to legitimize the controversial GcMAF field by developing a new, patent-protected formulation produced under GMP conditions and tested rigorously in clinical trials.

Therapeutic areas: OncologyInfectious Diseases
Modalities: Immunotherapy (macrophage activation)Protein biologics (modified vitamin D binding protein macrophage activator / GcMAF)
Industry: Biotech

Partnerships

No major pharma partnerships disclosed; manufacturing collaboration with Kamada for GMP production noted.

Beyond the preview

Go deeper on Efranat Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Efranat Ltd..